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Abstract
Purpose The purpose of this analysis was to develop a
population pharmacokinetic model for farletuzumab, a
humanized immunoglobulin (Ig)G1 monoclonal antibody
(mAb) to the folate receptor alpha, which is a receptor
over-expressed in ovarian cancer, but largely absent from
normal tissue.
Methods In total, 2,472 samples were included in the
building of the pharmacokinetic model. Farletuzumab
12.5–400 mg/m2 had been administered via intravenous
infusion to 79 patients with advanced ovarian cancer
enrolled in one of the two clinical studies. Data were
analyzed by a nonlinear mixed-effects modeling approach.
Results Farletuzumab pharmacokinetics was best descri-
bed by a two-compartment model with first-order (linear)
elimination. In the final model, estimated values of clearance
and volume of distribution of the central compartment were
0.00784 l/h and 3.00 l, respectively. Body weight was the
only covariate investigated that explained inter-patient var-
iability in clearance and the central volume of distribution.
There was no effect of age, human anti-human antibodies, or
concomitant chemotherapy on the pharmacokinetics of far-
letuzumab. Simulations showed that, when the mg/kg/week
dose was maintained, steady-state exposure to farletuzumab
was similar with dosing every week or every 3 weeks.
Conclusions The pharmacokinetic parameters of far-
letuzumab are similar to those of other IgG mAbs. The
results support weight-based dosing of farletuzumab on a
weekly or 3-weekly schedule.
Keywords Farletuzumab  Population pharmacokinetics 
Monoclonal antibody  Ovarian neoplasms  Folate receptor
alpha
Introduction
Ovarian cancer is the eighth most common cancer and fifth
most common cause of cancer death in women in the
United States [1]. The majority of women present with
advanced disease, which is often highly sensitive to first-
line chemotherapy treatment with platinum-based agents
and taxanes following maximal cytoreductive surgery.
However, most patients subsequently relapse and eventu-
ally die of disease persistence or recurrence resulting in
low long-term survival rates. Five-year survival for women
with ovarian cancer is approximately 45 % overall, but
only 25 % in women with ovarian cancer that has metas-
tasized [2]. Although the median survival of women with
advanced disease is improving, there remains a pressing
need for new approaches to enhance the management of
these individuals.
One potential novel target is the folate receptor a (FRa).
FRa is over-expressed in 90–100 % of epithelial ovarian
cancers [3–5], but has limited expression in normal tissue.
When FRa is expressed, it is restricted to the apical sur-
faces on polarized epithelial cells and is not exposed to the
bloodstream [6, 7]. FRa is an interesting target, as the
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degree of FRa over-expression is correlated with both the
stage and grade of disease and is a marker of more
aggressive disease [3, 4]. In addition, over-expression of
FRa enhances growth of tumorigenic cancer cells in vitro
and in vivo [8].
Farletuzumab (MORAb-003) is a humanized immuno-
globulin (Ig)G1 monoclonal antibody (mAb) directed
against FRa and is in phase III development for ovarian
cancer. In vitro, farletuzumab mediates complement-
dependent and antibody-dependent cytotoxicity in tumor
cell lines and inhibits FRa-dependent cell growth in CHO
cells over-expressing the receptor [9]. In vivo, the murine
LK26 FRa antibody (a precursor to farletuzumab) reduces
tumor growth in a mouse xenograft model [9].
Data from a phase I clinical trial (NCT00428766) have
shown farletuzumab to be generally well tolerated fol-
lowing intravenous (IV) administration and have provided
an early indication of efficacy in patients with advanced
ovarian cancer [10]. A small biodistribution sub-study
using radiolabeled farletuzumab showed good tumor
uptake of the mAb [11]. In a phase II trial (NCT00318370),
farletuzumab in combination with platinum-based chemo-
therapy normalized levels of the tumor marker, CA-125, in
approximately 90 % of women, and resulted in a second
remission equal to, or longer than, the first remission in
over 20 % of women [12]. Post hoc analysis showed the
overall response rates to farletuzumab were similar in
patients with first progression-free intervals of \12 and
C12 months [12].
In the phase I and II studies, farletuzumab pharmaco-
kinetics appeared to be dose-dependent [10, 12]. This paper
reports a pooled population pharmacokinetic analysis
based on data from the phase I and II studies, which aimed
to characterize the pharmacokinetics of farletuzumab in
patients with ovarian cancer, evaluate the effect of various
potential covariates on the pharmacokinetics, and use
simulations to support different dosing schedules.
Materials and methods
Study design and patients
The data used in this analysis were collected from two
studies in women with advanced epithelial ovarian cancer
conducted in accordance with Good Clinical Practice and
under ethical principles established by the Declaration of
Helsinki. All patients gave written informed consent.
The phase I study (NCT00428766; MORAb-003-001)
was conducted in 25 patients with advanced epithelial
ovarian, fallopian tube, or primary peritoneal cancer
who had relapsed after failed standard chemotherapy.
Farletuzumab was administered via IV infusion weekly for
4 weeks at ascending doses from 12.5 to 400 mg/m2 [10]
to sequential cohorts of patients. The phase II study
(NCT00318370; MORAb-003-002) was conducted in 54
patients with relapsed (asymptomatic or symptomatic)
platinum-sensitive epithelial ovarian cancer, defined by
elevated CA125 levels within 6–18 months of first remis-
sion. Patients received farletuzumab either as monotherapy
(asymptomatic patients) or in combination with standard
therapy (carboplatin and either paclitaxel or docetaxel). In
combination with chemotherapy, farletuzumab was ini-
tially to be administered to six patients at each dose of
37.5 mg/m2 and 62.5 mg/m2; all remaining patients
received farletuzumab at 100 mg/m2. Those responding to
combination therapy continued on single-agent far-
letuzumab as weekly maintenance therapy. In both studies,
infusions were commenced at 1 mg/min and advanced to
5 mg/min if tolerated.
Blood sampling and analysis
In the phase I study, blood samples were taken pre-dose, mid-
infusion, post–infusion, and at frequent intervals (30 min,
and 1, 2, 4, and 24 h post-dose) for a period of 24 h post-dose
(first and fourth dose) or 4 h (second and third dose). Addi-
tional sampling was conducted 2 weeks after the final dose. In
the phase II study, blood samples were taken pre- and post-
infusion weekly during cycle 1, then every 3 weeks. Addi-
tional samples were also taken 1 and 48 h post-infusion in
cycles 1, 2, and 3 (monotherapy arm) or all cycles (combi-
nation therapy arm) from the first 13 enrolled patients par-
ticipating in a pharmacokinetic sub-study.
Serum farletuzumab levels were assessed using a solid-
phase capture enzyme-linked immunosorbent assay (ELISA)
that used immobilized FRa to capture sample-based far-
letuzumab, followed by detection with a murine monoclonal
anti-MORAb-003 IgG and an enzyme-conjugated secondary
antibody. The low limit of quantitation was 3.13 ng/ml,
equivalent to 313 lg/ml in undiluted serum.
Population pharmacokinetic analysis
Pharmacokinetic data were analyzed using NONMEM
program version VI and VII level 1.0 and 2.0, NM-TRAN
version III level 1.0, and PREDPP version IV level 1.0
(ICON Development Solutions, Ellicott City, MD, USA).
Pharmacokinetic parameters were estimated using first-
order conditional estimation method with interaction
(FOCEI). Only patients with evaluable dosing, actual
sampling time, and farletuzumab concentration data were
included in the analysis.
The population pharmacokinetic model was devel-
oped in a stepwise manner with evaluation at each
step. Two initial pharmacokinetic models were assessed:
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a two-compartment model with either first-order elimina-
tion or with parallel Michaelis–Menten and first-order
elimination. Model selection was based on goodness of fit
plots, successful convergence, plausibility, and precision of
parameter estimates, and minimum objective function
value.
Distribution of inter-individual variability in the phar-
macokinetic parameters was assumed to be log-normal and
described by an exponential error model. Initial model
building used a diagonal covariance matrix of inter-indi-
vidual variability and a correlation between clearance and
volume of the central compartment was included in the
starting model. Residual error was modeled using com-
bined additive and proportional models. Separate residual
error terms were estimated for each of the two studies.
Covariate analyses were performed on clearance, vol-
ume of distribution of the central compartment and the
peripheral compartment, and apparent inter-compartmental
clearance. For covariates to be explored in the analysis, the
covariate was required to have C10 % presence and suf-
ficient range of values. Covariates included weight, body
size (body mass index [BMI], body surface area [BSA]),
age, human anti-human antibodies (HAHA), and concom-
itant chemotherapy.
Continuous covariates were entered into the model using
the following equation:
TVPi ¼ h1  COVi=COVSTð Þh2
where TVPi is the typical value of a pharmacokinetic
parameter (P) for an individual (i), COVi is the value of the
covariate in the individual, COVST is the median value of
the covariate in the study population, h1 represents the
typical value of the parameter, and h2 represents the effect
of the covariate on the parameter.
Categorical covariates were entered into the model using
the following equation:
TVPi ¼ h1  hIND2 i
where TVPi is the typical value of a pharmacokinetic
parameter (P) for an individual (i), h1 represents the typical
value of the parameter in the absence of the covariate
(when IND, the indicator variable, is equal to zero), and h2
is the fractional change in the typical value if the covariate
is present (IND = 1).
Covariates were modeled individually. Only those found
to influence pharmacokinetic parameters were included in
the final model. Significance was confirmed using a back-
ward elimination procedure.
The effective half-life (t1/2,eff) was calculated according
to the following equation:
t1=2;eff ¼ ln 2ð Þ=Keff
where Keff ¼ ln 1  AUCð0sÞ=AUCss;s
  
=s
where Keff is an effective rate constant, AUC(0–s) is the
area under the concentration time curve from 0 to s hours
following the first dose, AUCss,s is the AUC over a steady-
state dosing interval, and s is the dosing interval.
Model evaluation
The final farletuzumab population pharmacokinetics model
was used to simulate 250 replications of the observed
dataset. The observed data were compared with the fifth,
tenth, ninetieth, and ninety-fifth percentile of the simulated
data. The model was evaluated with a visual predictive
check, and the numbers of observed concentrations falling




The final pharmacokinetic dataset included 2,472 samples
from 79 women (Table 1).
Women were aged between 31 and 81 years with a
mean weight of 66.2 kg. In the phase I study, 15/25 women
had a Karnofsky performance status value of 90 % (10 with
Karnofsky status of 80 %), and in the phase II study, 36/54
had an ECOG performance status of 0 (18 with ECOG
status 1). All patients in the phase I study received far-
letuzumab monotherapy. In the phase II study, 28 patients
initially started on farletuzumab monotherapy; 21/28 went









































Asian 1 5 6
Hispanic 1 4 5
Other 5 0 5
BMI body mass index, BSA body surface area
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on to receive combination therapy and then 16/21 contin-
ued with farletuzumab monotherapy. Twenty-six patients
started on combination therapy and 20/26 continued with
farletuzumab monotherapy. Thus, over the course of the
two studies, farletuzumab monotherapy was received by 73
women, and farletuzumab in combination with standard
chemotherapy was received by 47 women.
On average, more than 30 samples were available per
patient. More than half of the samples in the analysis were
obtained from women receiving farletuzumab 100 mg/m2
(Table 2).
Population pharmacokinetic model
Combined data from both studies were best described by a
two-compartment model with first-order (linear, dose-
independent) elimination rather than a two-compartment
model with parallel Michaelis–Menten and first-order
elimination. There was some evidence of nonlinearity at
very low doses (namely, dose-dependency in clearance with
farletuzumab 12.5 and 25.0 mg/m2); however, analysis of
full datasets from both studies, with a two-compartment
model with parallel Michaelis–Menten and first-order
elimination, did not support nonlinearity. Therefore, the 169
observations at low doses (12.5 and 25.0 mg/m2) were
excluded for final model development and the two-
compartment model with first-order elimination applied to
the revised dataset.
In the base model, pharmacokinetic parameter estimates
for farletuzumab showed slow clearance (0.00830 l/h) and
small distribution volumes (3.00 l and 6.51 l for the vol-
ume of distribution of the central and peripheral compart-
ments, respectively). The inter-compartmental clearance
was 0.0213 l/h. The inter-individual variability for both
clearance and volume of distribution of the central com-
partment was \35 %, although inter-individual variability
of the peripheral volume of distribution was higher
(103 %).
The potential influence of several demographic/covari-
ate factors on the pharmacokinetics of farletuzumab was
explored. Body weight had the largest effect on clearance
and volume of distribution of the central compartment,
but had no effect on peripheral volume of distribution or
inter-compartmental clearance. Inclusion of BSA or BMI
into the model did not improve the accuracy of the model
to predict pharmacokinetic parameters. There was no
significant effect of age on any of the pharmacokinetic
parameters investigated. Additionally, a review of the
available HAHA data indicated that infrequent low-level
HAHA formation in study patients had no significant
impact on farletuzumab exposure. The effect of concomi-
tant chemotherapy on the pharmacokinetic parameters of
farletuzumab was investigated last and was found to
have no statistically or clinically significant effects on the
parameters tested.
The pharmacokinetic parameter estimates of the final
population model are shown in Table 3. Clearance was
estimated at 0.00784 l/h, and the volumes of distribution of
the central and peripheral compartments were estimated at
3.00 and 7.50 l, respectively. Inter-compartmental clear-
ance was estimated at 0.0203 l/h.
Weight had a greater influence on the volume of dis-
tribution of the central compartment than on clearance:
estimates of the exponents of weight-based allometric
scaling were 0.715 and 0.629, respectively, and relative
standard errors of these estimates were \36 %. With the
inclusion of weight as a covariate, the inter-individual
variability of clearance was reduced from 34.4 to 24.8 %,
and the inter-individual variability of the central volume of
distribution was reduced from 25.6 to 21.7 %.
The residual variability estimated for the phase II study
was higher than that for the phase I study (34.9 and 20.5 %,
respectively).
Model evaluation
The diagnostic plots of predicted and observed data (Fig. 1)
indicated that the model described the observed plasma
farletuzumab concentration data well. Re-introduction of
the 169 observations associated with farletuzumab 12.5 and
25.0 mg/m2 had little impact on clearance and the central
volume of distribution estimates, but increased inter-indi-
vidual variability and resulted in the effect of body weight
on these parameters being less well estimated.
The visual predictive check of the final pharmacokinetic
model confirmed the suitability of the model (Fig. 2). Only
9.37 % of observations fell outside the 90 % prediction
interval.

















12.5 3 81 – – 3 81
25.0 3 88 – – 3 88
37.5 3 89 4 211 7 300
62.5 3 90 5 250 8 340
100.0 3 91 45 1,289 48 1,380
200.0 3 95 – – 3 95
400.0 7 188 – – 7 188
Total 25 722 54 1,750 79 2,472
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Half-life calculations
Using the individual pharmacokinetic parameter estimates
from the final model, the alpha (distribution) and beta
(elimination) half-lives of farletuzumab were calculated to
be 2.48 (95 % confidence interval [CI] 1.00, 3.38) days and
49.2 (95 % CI 14.6, 173.0) days, respectively. Based on an
accumulation ratio of 3.11 following farletuzumab dosing
once weekly, the effective or functional half-life of far-
letuzumab was calculated to be approximately 12.5 days.
Discussion
This is the first population pharmacokinetic model devel-
oped for farletuzumab using combined data from a phase I
and a phase II study. Farletuzumab pharmacokinetics
were best described by a two-compartment model with
linear elimination over a dose range of 37.5–400 mg/m2,
although there was some evidence of nonlinear pharma-
cokinetics at very low farletuzumab doses (12.5 and
25.0 mg/m2). A two-compartment model has been used
previously to describe the pharmacokinetic data of all
intravenously administered monoclonal antibodies, many
(e.g., bevacizumab, pertuzumab, and trastuzumab) with
linear first-order clearance, independent of dose [13–15].
The nonlinearity at very low doses has also been observed
previously with bevacizumab [14], where clearance was
2–3 times faster with doses of 0.1 and 0.3 mg/kg than at
doses C1 mg/kg. As the farletuzumab 12.5 and 25.0 mg/
m2 doses are considerably lower than doses proposed for
further clinical study, it was considered appropriate to
exclude them from the final model.
Estimates showed farletuzumab had a small volume
of distribution (indicating limited tissue penetration) and
slow clearance (0.188 l/day) comparable to that of other
monoclonal antibodies (0.207 l/day for bevacizumab,
0.214 l/day for pertuzumab, and 0.225 l/day for trast-
uzumab) [13–15]. The large molecular weight of mAbs and
their hydrophilicity/polarity explain the consistently small
volumes of distribution of farletuzumab and other mAbs.
Central and peripheral volumes of distribution are in the
range 2.4–5.5 l and 1.3–7.5 l, respectively [16].
Covariates of size (weight, BMI, and BSA) are the most
frequently identified and clinically relevant covariates of
the pharmacokinetics of mAbs [16]. In this analysis, weight
was found to influence both farletuzumab clearance and
central volume of distribution. Inclusion of weight within
the model reduced the inter-individual variability of
clearance and central volume of distribution, but inclusion
of either BSA or BMI within the model did not improve its
accuracy. This is consistent with what was expected on the
Table 3 Parameter estimates for the final population pharmacokinetic model
Estimate % RSE 95 % CI
Parameter
CL (l/h) 0.00784 5.79 0.00695, 0.00873
Vc (l) 3.00 5.20 2.69, 3.31
Q (l/h) 0.0203 4.46 0.0185, 0.0221
Vp (l) 7.50 20.30 4.52, 10.50
Covariate influence
CL * WT 0.715 35.2 0.221, 1.210
Vc * WT 0.629 30.2 0.257, 1.000
Inter-individual variability % CV
x2 CL 0.0616 27.8 0.0281, 0.0951 24.8
x2 Vc 0.0470 33.6 0.0160, 0.0780 21.7
x2 Vp 1.180 21.3 0.688, 1.670 109.0
Residual variability % CV or SD
Phase I study
r2 proportional (% CV) 0.0420 5.07 0.0378, 0.0462 20.5
r2 additive (SD lg/ml) 0 (fixed) – – –
Phase II study
r2 proportional (% CV) 0.122 1.87 0.118, 0.126 34.9
r2 additive (SD lg/ml) 63.0 4.71 57.2, 68.8 7.94
%RSE percent relative standard error of the estimate, x2 variance of the inter-individual random effect, r2 variance of the residual intra-
individual random error, CI confidence interval, CL clearance, CV coefficient of variation, Q apparent inter-compartmental clearance, SD
standard deviation, Vc volume of distribution of the central compartment, Vp volume of distribution of the peripheral compartment, WT weight
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basis of other population pharmacokinetic analyses where
weight is most commonly included in the final model [16].
Accordingly, and aligned with the approved dosing of
approved mAbs, ongoing studies of farletuzumab in ovar-
ian cancer and other tumor types are using weight-based,
mg/kg, dosing.
The other covariates investigated, including age, did not
affect farletuzumab pharmacokinetic parameters in this
model. In other analyses, age has only been identified as a
covariate in the population pharmacokinetic analysis of
efalizumab [17] (which was attributed to the subcutaneous
route of administration of efalizumab and the aging char-
acteristics of the skin) and panitumumab [18].
Concomitant chemotherapy also did not affect far-
letuzumab pharmacokinetic parameters. Because mAbs are
not substrates for the enzyme systems, such as cytochrome
P450, involved in the metabolism of small molecules,
pharmacokinetic drug–drug interactions between mAbs
and small-molecule chemotherapy are not anticipated [19].
Indeed, these have not been shown with other mAbs other
than with a couple of exceptions [16, 19], although the
ongoing potential for drug–drug interactions is being
investigated in studies with farletuzumab where combina-
tion therapy is being given.
As mAbs are exogenous proteins, they can elicit an
immune response with endogenous antiglobulins targeting
the mAb. Despite the assay method used to detect HAHA
to farletuzumab being extremely sensitive (lower limit of
detection of 8 ng/ml), HAHA incidence level was very
low, and the vast majority of the positive values were
threshold responses, close to the assay cut-off point in both
the phase I and phase II studies [10, 12]. Given the low
magnitude in all but a few patients, these immune
responses were unlikely to alter farletuzumab pharmaco-
kinetics significantly.
Although formation of HAHA and binding of these to
farletuzumab could alter elimination rates (as the resulting
immune complexes are cleared more quickly than IgG1
antibodies), a review of the available HAHA data indicated
no clear impact on farletuzumab exposure. It should be
noted, however, that the presence of elevated levels of free
unbound drug in serum samples may confound the detec-
tion and impact of HAHA, in particular against far-
letuzumab, as method validation demonstrated drug
tolerance of approximately 100 ng/ml. Nevertheless, the
low level of HAHA formation coupled with high circu-
lating farletuzumab concentrations makes it unlikely that
any immunocomplexes significantly altered the pharma-
cokinetic evaluation.
Gender and race were not investigated as covariates, as
all patients were female and the majority were Caucasian.
Although gender has been identified as a predictor of
clearance and the volume of distribution of the central
compartment with a minority of mAbs, including bev-
acizumab [14], the magnitude of the effect is not sufficient
to require dose adjustments in males compared with
females. Although all completed studies with farletuzumab
thus far have involved women, current investigations in
other tumor types involve patients of both genders. Race
has not been found to influence the pharmacokinetics of
many mAbs [16]. Similarly, as expected from the limited
involvement of the kidney and liver in the clearance of
mAbs, hepatic and renal functions have rarely been iden-
tified as covariates in population pharmacokinetic analyses
of mAbs [16, 20] and were not investigated as covariates in
the farletuzumab model.
Residual variability was modeled using combined pro-
portional and additive components for each study. The
proportional residual variability associated with the phase
II study was higher than that for the phase I study, but both
were consistent with the proportional residual variability of
other MAb pharmacokinetic models (8.8–42.0 % [16]).
The lower residual variability in the phase I study is not
unexpected given that timings associated with drug
administration and blood sampling tend to be managed
particularly stringently in phase I studies.
Using elimination half-life as an indication of dosing
frequency is scientifically reasonable for most drugs with
rapid absorption. However, elimination half-life alone
cannot be used to guide dosing frequency for drugs with
extended absorption or for drugs with multiphasic dispo-
sition where the contribution of the terminal phase to
steady-state exposure is limited. In such cases, an ‘effec-
tive’ or ‘functional’ half-life pharmacokinetic parameter
better guides dosing frequency [21]. In this analysis, the
effective half-life of farletuzumab (estimated at 12.5 days)
was much shorter than the elimination half-life, suggesting
the elimination half-life makes a relatively small contri-
bution to the accumulation of farletuzumab when admin-
istered once weekly. Dose simulation studies (Eisai, data
on file) predicted that farletuzumab accumulation over a
3-week period is similar with 3-weekly dosing compared
with once-weekly dosing, when farletuzumab is dosed at 3
times the weekly dose. Within the ongoing clinical devel-
opment program for farletuzumab, a variety of different
dosing schedules are being employed.
In summary, farletuzumab accumulation to steady state
can be predicted by a linear two-compartment pharmaco-
kinetic model. The pharmacokinetic parameters of far-
letuzumab and observed variability of these parameters are
typical of other IgG mAbs. Identification of weight as the
covariate with the greatest influence of farletuzumab
pharmacokinetics supports dosing on a mg/kg basis. Sim-
ilar exposure to farletuzumab can be achieved indepen-
dently of dosing schedule, with the results supporting
dosing of farletuzumab every 1, 2, or 3 weeks.
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